Spots Global Cancer Trial Database for A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Official Title: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Study ID: NCT04924192
Conditions
Study Description
Brief Summary: This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
The Second Affiliated Hospital of PLA Air Force Military Medical University, Xi'an, Shanxi, China
West China Hospital of Sichuan University, Chengdou, Sichuan, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Yunnan Cancer Hospital, Kunming, Yunnan, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
